Policy Action to Protect Access to Essential Medicines
Policy changes that enable more nimble pricing, reimbursement and procurement models for off-patent medicines, accommodating current inflation levels, may help alleviate the risk of further medicine shortages. The off-patent medicines industry is encouraging policymakers to exclude off-patent medicines from price cutting measures, including claw-backs, external reference pricing, and other mechanisms that compromise the economic viability of medicines and therefore limit patient access.